<DOC>
	<DOCNO>NCT01361945</DOCNO>
	<brief_summary>The purpose study find effect , administer infusion AUY922 hormonal therapy ( letrozole ) oral target drug ( lapatinib ) patient advance breast cancer know ER+ HER2 + .</brief_summary>
	<brief_title>AUY922 With Lapatinib Letrozole ER+ HER2+ Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Age 18 year Able sign Informed Consent Patients must follow laboratory value : Absolute Neutrophil Count ( ANC ) 1.5x109/L Hemoglobin ( Hgb ) 9 g/dl Platelets ( plt ) 100x109/L Potassium within normal limit Total calcium ( correct serum albumin ) Phosphorus within normal limit Magnesium LLN correctable supplement AST/SGOT ALT/SGPT ≤ 1.5 x Upper Limit Normal ( ULN ) AP &gt; 2.5 ULN AST/SGOT ALT/SGPT ≤ 2.5 x Upper Limit Normal ( ULN ) AP ≤ 5.0 x ULN Serum bilirubin 1.5 x ULN Serum creatinin 1.5 x ULN 24hour clearance 50 ml/min Negative serum pregnancy test . The serum pregnancy test must obtain prior first administration AUY922 ( ≤ 72 hour prior dose ) premenopausal woman woman &lt; 2 year onset menopause Histologically confirm HER2 + ER+ PR + ( i.e. , HR+ ) Postmenopausal woman Metastatic breast cancer resistant locally advanced breast cancer . Stage disease ( stage IIIb/c respond progress standard therapy trastuzumab ) stage IV receive first line treatment metastatic setting . All patient document clinical progression prior enter study Prior chemotherapy metastatic stage IV disease prohibit patient enrolled phase II , allow 3 line patient enrol Phase I . Prior neoadjuvant/adjuvant chemotherapy , antiestrogens , radiotherapy allow . Adjuvant hormonal therapy include aromatase inhibitor permit adjuvant , neoadjuvant metastatic set discontinue least two week prior start study treatment . Trastuzumab permit adjuvant , neoadjuvant metastatic set discontinue least 4 week prior study treatment Patients must least one measurable lesion define RECIST . Irradiated lesion nonmeasurable disease evaluable disease progression Patients must tumors carry HER2 gene amplification determine ( ) fluorescence situ hybridization ( FISH ) ( ii ) overexpression HER2 protein 3+ level assess immunohistochemistry . Patients previously treat trastuzumab must treatment least 6 week prior start study treatment . World Health Organization ( WHO ) Performance Status &lt; 1 Life expectancy &gt; 12 week Unresolved diarrhea ≥ CTCAE ( v4.02 ) grade 1 Pregnant lactate woman Impaired cardiac function , include one following : History ( family history ) long QT syndrome Mean QTc ≥ 450 msec baseline ECG History clinically manifest ischemic heart disease ≤ 6 month prior study start History heart failure leave ventricular ( LV ) dysfunction ( LVEF ≤ 45 % ) MUGA ECHO arrythmia Patients know HIV positive . Testing required absence clinical sign symptom suggest HIV infection . Known hypersensitivity study drug excipients Participation another clinical study within 30 day first study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>ER+</keyword>
	<keyword>HER2+</keyword>
	<keyword>Breast</keyword>
</DOC>